Technical Analysis for OCUL - Ocular Therapeutix, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.20 | -9.58% | -0.45 |
Earnings due: May 6
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | -9.58% | |
| Lower Bollinger Band Walk | Weakness | -9.58% | |
| Wide Bands | Range Expansion | -9.58% | |
| Below Lower BB | Weakness | -9.58% | |
| Down 3 Days in a Row | Weakness | -9.58% | |
| Down 4 Days in a Row | Weakness | -9.58% | |
| Down 5 Days in a Row | Weakness | -9.58% | |
| Lower Bollinger Band Touch | Weakness | -9.58% | |
| Oversold Stochastic | Weakness | -9.58% | |
| Calm After Storm | Range Contraction | -16.00% |
| Alert | Time |
|---|---|
| Down 10% | about 2 hours ago |
| 60 Minute Opening Range Breakdown | about 6 hours ago |
| Rose Above Lower Bollinger Band | about 7 hours ago |
| Down 5% | about 7 hours ago |
| Down 3% | about 7 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/06/2024
Ocular Therapeutix, Inc. Description
Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company's earlier stage product candidates include OTX-DP, which is in Phase II clinical trials for the treatment of allergic conjunctivitis; OTX-MP that has completed Phase I clinical trials for the treatment of bacterial conjunctivitis; and Anti-VEGF hydrogel depot, which is in preclinical testing for the treatment of wet AMD. Ocular Therapeutix, Inc. sells its ReSure Sealant through a network of independent medical device distributors in the United States. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Eye Inflammation Hypertension Clinical Trial Sealant Glaucoma Platform Technology Eye Diseases Cataracts Incision Treatment Of Glaucoma Allergic Conjunctivitis Cataract Surgery Cornea Allergology Incisions Ocular Hypertension Post Surgical Ocular Inflammation
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.31 |
| 52 Week Low | 1.995 |
| Average Volume | 2,612,359 |
| 200-Day Moving Average | 4.92 |
| 50-Day Moving Average | 8.59 |
| 20-Day Moving Average | 7.51 |
| 10-Day Moving Average | 6.52 |
| Average True Range | 0.59 |
| RSI (14) | 16.67 |
| ADX | 32.82 |
| +DI | 11.02 |
| -DI | 43.72 |
| Chandelier Exit (Long, 3 ATRs) | 8.01 |
| Chandelier Exit (Short, 3 ATRs) | 6.34 |
| Upper Bollinger Bands | 10.38 |
| Lower Bollinger Band | 4.65 |
| Percent B (%b) | 0.0 |
| BandWidth | 76.23 |
| MACD Line | -0.98 |
| MACD Signal Line | -0.59 |
| MACD Histogram | -0.3918 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.32 | ||||
| Resistance 3 (R3) | 5.37 | 5.19 | 5.21 | ||
| Resistance 2 (R2) | 5.19 | 5.02 | 5.17 | 5.17 | |
| Resistance 1 (R1) | 4.92 | 4.91 | 4.83 | 4.87 | 5.13 |
| Pivot Point | 4.74 | 4.74 | 4.69 | 4.72 | 4.74 |
| Support 1 (S1) | 4.47 | 4.57 | 4.38 | 4.42 | 4.16 |
| Support 2 (S2) | 4.29 | 4.46 | 4.27 | 4.12 | |
| Support 3 (S3) | 4.02 | 4.29 | 4.08 | ||
| Support 4 (S4) | 3.97 |
